Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) had its price target boosted by analysts at Credit Suisse Group from $61.00 to $66.00 in a note issued to investors on Thursday, November 2nd. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective indicates a potential upside of 11.00% from the company’s current price.
A number of other brokerages have also recently commented on AGIO. BidaskClub cut Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $80.00 price objective (up from $68.00) on shares of Agios Pharmaceuticals in a research note on Tuesday, August 8th. Needham & Company LLC lifted their price objective on Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, August 10th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $83.00 target price (up from $75.00) on shares of Agios Pharmaceuticals in a research note on Thursday, August 10th. Finally, Leerink Swann raised Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $50.00 to $80.00 in a research note on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $75.70.
Agios Pharmaceuticals (NASDAQ:AGIO) opened at $59.46 on Thursday. Agios Pharmaceuticals has a 52-week low of $39.24 and a 52-week high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. The firm had revenue of $11.35 million during the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The business’s revenue for the quarter was up 26.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.63) EPS. equities analysts predict that Agios Pharmaceuticals will post -6.59 EPS for the current year.
In other news, CEO David P. Schenkein sold 6,000 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $62.20, for a total value of $373,200.00. Following the completion of the transaction, the chief executive officer now directly owns 6,000 shares in the company, valued at approximately $373,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $71.10, for a total value of $284,400.00. Following the completion of the transaction, the director now owns 84,394 shares of the company’s stock, valued at $6,000,413.40. The disclosure for this sale can be found here. Insiders sold 178,908 shares of company stock worth $12,147,719 in the last ninety days. 10.55% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in AGIO. BlackRock Inc. raised its position in Agios Pharmaceuticals by 8,463.5% during the 1st quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after purchasing an additional 2,141,768 shares during the last quarter. FMR LLC raised its position in shares of Agios Pharmaceuticals by 14.1% in the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after acquiring an additional 895,584 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Agios Pharmaceuticals by 23.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after acquiring an additional 617,379 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Agios Pharmaceuticals by 748.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 649,124 shares of the biopharmaceutical company’s stock worth $37,909,000 after acquiring an additional 572,579 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth about $20,423,000. 93.16% of the stock is owned by institutional investors and hedge funds.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.